Status:
COMPLETED
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules
Lead Sponsor:
XiangNing Fu
Conditions:
Multiple Pulmonary Nodules
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules: a pilot study
Detailed Description
In many cases, non-small-cell lung cancer(NSCLC) manifested as synchronous ground-glass nodules(GGNs) and makes complete surgical resection impossible. At the same time, there is no good solution for ...
Eligibility Criteria
Inclusion
- not less than two GGNs on chest CT
- at least one lesion is diagnosed as NSCLC from biopsy pathology
- no contraindication for surgery
- ECOG score of 0 or 1
- no detectable evidence of distant metastasis
Exclusion
- medical history of malignancy
- pregnant or breeding period
- severe organ failure (heart, liver, kidney, and lung)
- high risk of cerebral-cardiovascular evens
- infection out of control
- received or receiving chemo- and radiotherapy
- history of severe reaction due to allergy or hypersensitivity
- severe mental disorder
- currently been enrolled in other trials
- autoimmune or chronic inflammatory disease
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2025
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04047186
Start Date
July 1 2019
End Date
May 30 2025
Last Update
September 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital Affiliated to Huazhong Technology Hospital
Wuhan, Hubei, China, 430030